Level 1 - Clinical Execution Readiness

At this stage, biotech teams often ask:

• What structural blind spots could compromise our first clinical execution?

• Do we have the right internal governance in place?

• Have the different outsourcing models been assessed?

• Is our budget forecast aligned with realistic clinical execution costs?

• Would our clinical execution plan stand up to investor diligence?

• Are we approaching CRO selection strategically or reactively?

• Are we committing to CRO partners before fully understanding our execution risk?

• What risks are we not foreseeing yet?

Is this stage familiar?

If this stage feels familiar, run a CRO readiness check in 2 minutes.

Governance & Decision Structure

• Clarity of roles and internal accountability

• Board vs operational decision pathways

• External clinical advisory and investor governance

Clinical Strategy Positioning

• Development roadmap clarity

• Protocol maturity level

• Regulatory timing alignment

Capital Exposure Before Vendor Commitment

• Financial runway vs realistic clinical execution cost

• Sensitivity to scope changes

• Capital allocation risk

What We Assess

Outsourcing Approach

• Clinical outsourcing governance

• CRO engagement strategy

• Geographic model assumptions

• Operational oversight expectations

Risk Exposure Mapping

• Asset complexity risks

• Operational dependency risks

• Financial exposure triggers

• Investor diligence vulnerability points

Executive-level diagnostic to assess clinical execution readiness before major capital and CRO commitments:

What You Receive

Structured CRO Readiness Report

A structured assessment summarizing strengths, gaps, and priority actions.

CRO Readiness Score

A proprietary model-based scoring framework across key operational and financial dimensions.

Clinical Entry Budget Benchmark

Independent tailored-budget orientation aligned with operational assumptions and trial complexity.

CRO Pre-Selection list

A high-level CRO landscape orientation identifying vendor types structurally aligned with your anticipated clinical entry.

Executive Strategic Debrief Session

Executive-level discussion of findings and recommended next steps.

Level 1 ensures your first clinical step is intentional, structured, and strategically defensible.

Engagement scope and investment vary depending on trial complexity and stage. All collaborations begin with a structured exploratory discussion.